Encephalopathy autoimmune evaluation, spinal fluid

Alphabetical Test listing

Encephalopathy autoimmune evaluation, spinal fluid-12689

  
Encephalopathy autoimmune evaluation, spinal fluid
  
12689
  
LAB12689
  
ENC1
  
Paraneoplastic
  
  • Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in spinal fluid specimens

    The following accompaniments should increase of suspicion for autoimmune encephalopathy:
    • Headache
    • Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
    • History of cancer
    • Smoking history (20+ pack years) or other cancer risk factors
    • Inflammatory cerebral spinal fluid (or isolated protein elevation)
    • Neuroimaging signs suggesting inflammation
  • Evaluating limbic encephalitis (noninfectious)
  • Directing a focused search for cancer
  • Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect
  
Cerebrospinal fluid (CSF)
  

Sterile vial/container

  
4.0 mL
  
2.0 mL
  

Sterile vial/container

  

Refrigerated (preferred) - 28 days

Frozen - 28 days

Ambient - 72 hrs

  
Mayo Clinic Laboratories (ENC2): R-MM
  
Daily
  
8 - 11 days
  

Indirect Immunofluorescence Assay (IFA), Cell Binding Assay (CBA), Western Blot (WB) and Immunoprecipitin Assay (IPA)

  
86255 x19
86341

Additional CPT codes (if appropriate):
84182 x 7
86255 x 7
86256 x 8
  
11/18/2014
  
07/16/2021
  
02/24/2020